Cargando…

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

BACKGROUND: In clinical practice the gold standard method to assess BRAF status in patients with metastatic melanoma is based on molecular assays. Recently, a mutation-specific monoclonal antibody (VE1), which detects the BRAF V600E mutated protein, has been developed. With this study we aimed to co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schirosi, Laura, Strippoli, Sabino, Gaudio, Francesca, Graziano, Giusi, Popescu, Ondina, Guida, Michele, Simone, Giovanni, Mangia, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116153/ https://www.ncbi.nlm.nih.gov/pubmed/27863476 http://dx.doi.org/10.1186/s12885-016-2951-4

Ejemplares similares

microRNAs and next generation sequencing for the prognosis of the metastatic melanoma
por: Pinto, Rosamaria, et al.
Publicado: (2015)

Immunoprofile from tissue microarrays to stratify familial breast cancer patients
por: Schirosi, Laura, et al.
Publicado: (2015)

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma
por: Rusu, Stefan, et al.
Publicado: (2021)

NRAS(Q61R), BRAF(V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas
por: Uguen, Arnaud, et al.
Publicado: (2015)

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
por: Meevassana, Jiraroch, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
por: Schirosi, Laura, et al.
Publicado: (2019)

Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
por: Garrisi, Vito Michele, et al.
Publicado: (2014)

Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry
por: Urvanegia, Ana Claudia, et al.
Publicado: (2017)

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response
por: Pinto, Rosamaria, et al.
Publicado: (2016)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients
por: Schirosi, Laura, et al.
Publicado: (2016)

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
por: Gow, Chien-Hung, et al.
Publicado: (2019)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

VE1 immunohistochemistry is an adjunct tool for detection of BRAF (V600E) mutation: Validation in thyroid cancer patients
por: Rashid, Faiza A., et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
por: Ida, Cristiane M, et al.
Publicado: (2013)

BRAF‐V600E immunohistochemistry in a large series of glial and glial–neuronal tumors
por: Breton, Quentin, et al.
Publicado: (2017)

Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues
por: Zhang, Yini, et al.
Publicado: (2021)

A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma
por: Lo, Michelle Chin I, et al.
Publicado: (2016)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
por: Ponti, Giovanni, et al.
Publicado: (2012)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer
por: Schafroth, Christian, et al.
Publicado: (2015)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status
por: Guida, Gabriella, et al.
Publicado: (2014)

BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas
por: Manninen, Atte A., et al.
Publicado: (2019)

Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay
por: Vallée, Audrey, et al.
Publicado: (2019)

VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAF(V600E) Mutation in Papillary Thyroid Cancer
por: Choden, Sonam, et al.
Publicado: (2020)

Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanomas
por: Giovanni, Ponti, et al.
Publicado: (2014)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mv47nauq0lfacc896up4ui3e1f